These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 3293977)

  • 1. Cefotaxime optimal dosage in adult patients. A reappraisal.
    Simon A; d'Aubrac CA; Safran C; Carbon C
    Drugs; 1988; 35 Suppl 2():221-30. PubMed ID: 3293977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftizoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Richards DM; Heel RC
    Drugs; 1985 Apr; 29(4):281-329. PubMed ID: 3888599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.
    Carmine AA; Brogden RN; Heel RC; Speight TM; Avery GS
    Drugs; 1983 Mar; 25(3):223-89. PubMed ID: 6303743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections.
    Plosker GL; Foster RH; Benfield P
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 1):91-106. PubMed ID: 10175990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro interaction between ofloxacin and cefotaxime against gram-positive and gram-negative bacteria involved in serious infections.
    Gimeno C; Borja J; Navarro D; Valdés L; García-Barbal J; García-de-Lomas J
    Chemotherapy; 1998; 44(2):94-8. PubMed ID: 9551238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.
    Brogden RN; Spencer CM
    Drugs; 1997 Mar; 53(3):483-510. PubMed ID: 9074846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cephalosporins--cefotaxime 10 years later, a major drug with continued use.
    Neu HC
    Infection; 1991; 19 Suppl 6():S309-15. PubMed ID: 1791075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Third-generation cephalosporins.
    Klein NC; Cunha BA
    Med Clin North Am; 1995 Jul; 79(4):705-19. PubMed ID: 7791418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.
    Richards DM; Heel RC; Brogden RN; Speight TM; Avery GS
    Drugs; 1984 Jun; 27(6):469-527. PubMed ID: 6329638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefotaxime dosage in infants and children. Pharmacokinetic and clinical rationale for an extended dosage interval.
    Kearns GL; Young RA; Jacobs RF
    Clin Pharmacokinet; 1992 Apr; 22(4):284-97. PubMed ID: 1606788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic options for cefotaxime in the management of bacterial infections.
    Raddatz JK; Ostergaard BE; Rotschafer JC
    Diagn Microbiol Infect Dis; 1995; 22(1-2):77-83. PubMed ID: 7587054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of frequency of administration on therapeutic efficacy of cefotaxime.
    Parker RH
    Clin Ther; 1984; 6(4):488-99. PubMed ID: 6088045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftriaxone against gram-negative and gram-positive bacteria: bactericidal and post-antibiotic effect.
    Ravizzola G; Bonfanti C; Savoldi E; Turano A
    Chemioterapia; 1985 Jun; 4(3):204-8. PubMed ID: 3875430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefodizime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Barradell LB; Brogden RN
    Drugs; 1992 Nov; 44(5):800-34. PubMed ID: 1280568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefotaxime in the treatment of meningitis.
    Cherubin CE; LeFrock J
    Infection; 1985; 13 Suppl 1():S68-72. PubMed ID: 4055058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
    Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA
    Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Review of oral cephalosporins. Basis for a rational choice].
    Forti IN
    Medicina (B Aires); 1994; 54(5 Pt 1):439-58. PubMed ID: 7658980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review and reassessment of dosing schedules for cefotaxime in selected medical indications.
    Young LS
    Diagn Microbiol Infect Dis; 1995; 22(1-2):147-54. PubMed ID: 7587030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal cefotaxime dosing for gram-negative bacteremia: effective trough serum bactericidal titers and drug concentrations 8 and 12 hr after 1- or 2-gm infusions.
    Goodpasture HC; Gerlach EH; Jones RN; Peterie JD
    Diagn Microbiol Infect Dis; 1988 Feb; 9(2):97-103. PubMed ID: 3383550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical experience of cefotaxime (author's transl)].
    Portier H; Carbon C; Boussougant Y; Destaing F
    Nouv Presse Med; 1981 Feb; 10(8):607-11. PubMed ID: 6259603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.